Viread: adverse event reports filed with FDA

22,033

reports as suspect product

0.1% of all reports · about 979 a year

195

reports, 12 months to June 2026

462 in the 12 months before

94.5%

marked serious by the reporter

88.4% across the class

3.6%

record death among outcomes, as reported

795 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Viread reports recording the termmedian drug in hepatitis b virus nucleoside analog reverse transcriptase inhibitor

1. Bone density decreased48.4%10,656
2. Renal injury41.9%9,241
3. Skeletal injury37.8%8,328
4. Osteonecrosis32.7%7,205
5. Chronic kidney diseaselong-term kidney disease32.5%7,157
6. Bone loss32.1%7,073
7. Multiple fractures31%6,829
8. Renal failurekidney failure29.6%6,515
9. Osteoporosisthinning of the bones23.5%5,169
10. Tooth loss20.5%4,521
11. Painpain, site not specified13.2%2,915
12. Emotional distressemotional distress12.9%2,851
13. Anxietyanxiety11.7%2,588
14. Anhedonia11.1%2,454
15. Osteopenia10.1%2,215
16. Tooth injury9.1%2,012
17. Blood creatinine increasedraised creatinine, a kidney test6.6%1,456
18. Renal impairmentreduced kidney function5.8%1,269
19. Nephropathy4.7%1,042
20. Acute kidney injurysudden loss of kidney function4.6%1,017
21. Economic problema financial problem4.1%900
22. Fracturea broken bone3.5%769
23. End stage renal diseasekidney failure needing dialysis or transplant2.5%547
24. Vitamin D deficiencylow vitamin D2.2%483
25. Bone disorder2.1%460
26. Protein total abnormal2%446
27. Fanconi syndrome acquired1.9%423
28. Depressionlow mood1.9%421
29. Foot fracture1.9%415
30. Drug ineffectivethe medicine did not work as expected1.6%359

Top 30 of 1,327 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 12 drugs in the hepatitis b virus nucleoside analog reverse transcriptase inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 72,523 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 79.4% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 22,033 reports.

Drugs most often listed in the same reports

Other products listed in reports where Viread is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the hepatitis b virus nucleoside analog reverse transcriptase inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Viread as a suspect or interacting product; reports listing it only as a concomitant medication (2,347) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.